Ubs Group Ag Adma Biologics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 2,421,623 shares of ADMA stock, worth $33.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,421,623

Previous 2,816,814 14.03%

Holding current value

$33.9 Million

Previous $55.9 Million 21.09%

% of portfolio

0.01%

Previous 0.01%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$17.6 - $24.51 $6.96 Million - $9.69 Million	-395,191 Reduced 14.03%	2,421,623 $44.1 Million
Q1 2025 May 13, 2025	BUY	$15.44 - $20.61 $28 Million - $37.4 Million	1,812,882 Added 180.58%	2,816,814 $55.9 Million
Q4 2024 Feb 14, 2025	BUY	$15.62 - $22.62 $9.16 Million - $13.3 Million	586,227 Added 140.34%	1,003,932 $17.2 Million
Q3 2024 Nov 14, 2024	BUY	$11.21 - $20.03 $490,639 - $876,673	43,768 Added 11.7%	417,705 $8.35 Million
Q2 2024 Aug 13, 2024	SELL	$5.98 - $11.18 $1.15 Million - $2.14 Million	-191,494 Reduced 33.87%	373,937 $4.18 Million
Q1 2024 May 13, 2024	BUY	$4.4 - $6.74 $295,380 - $452,469	67,132 Added 13.47%	565,431 $3.73 Million
Q4 2023 Feb 09, 2024	BUY	$3.08 - $4.52 $832,092 - $1.22 Million	270,160 Added 118.42%	498,299 $2.25 Million
Q3 2023 Nov 09, 2023	SELL	$3.47 - $4.61 $193,650 - $257,270	-55,807 Reduced 19.65%	228,139 $816,000
Q2 2023 Aug 11, 2023	SELL	$3.12 - $4.22 $312,324 - $422,438	-100,104 Reduced 26.07%	283,946 $1.05 Million
Q1 2023 May 12, 2023	SELL	$3.01 - $3.87 $476,958 - $613,232	-158,458 Reduced 29.21%	384,050 $1.27 Million
Q4 2022 Feb 08, 2023	BUY	$2.47 - $3.88 $1.18 Million - $1.86 Million	479,078 Added 755.29%	542,508 $2.1 Million
Q3 2022 Nov 10, 2022	BUY	$2.03 - $2.86 $128,762 - $181,409	63,430 New	63,430 $154,000
Q2 2022 Aug 10, 2022	SELL	$1.43 - $2.2 $16,294 - $25,069	-11,395 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.28 - $1.83 $14,585 - $20,852	11,395 New	11,395 $21,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.66 $20,094 - $30,602	-18,435 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.13 - $1.65 $15,209 - $22,209	13,460 Added 270.55%	18,435 $21,000
Q2 2021 Aug 13, 2021	SELL	$1.51 - $2.07 $23,311 - $31,956	-15,438 Reduced 75.63%	4,975 $8,000
Q1 2021 May 12, 2021	SELL	$1.67 - $2.95 $2,443 - $4,315	-1,463 Reduced 6.69%	20,413 $36,000
Q4 2020 Feb 11, 2021	BUY	$1.8 - $2.56 $31,903 - $45,373	17,724 Added 426.88%	21,876 $43,000
Q3 2020 Nov 12, 2020	SELL	$2.04 - $3.74 $67,295 - $123,375	-32,988 Reduced 88.82%	4,152 $10,000
Q2 2020 Jul 31, 2020	BUY	$2.42 - $3.29 $5,338 - $7,257	2,206 Added 6.31%	37,140 $109,000
Q1 2020 May 01, 2020	SELL	$1.5 - $4.59 $34,111 - $104,381	-22,741 Reduced 39.43%	34,934 $100,000
Q4 2019 Feb 14, 2020	SELL	$3.89 - $5.15 $25,475 - $33,727	-6,549 Reduced 10.2%	57,675 $231,000
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $188,927 - $319,222	59,225 Added 1184.74%	64,224 $286,000
Q2 2019 Aug 14, 2019	BUY	$3.52 - $5.24 $12,584 - $18,733	3,575 Added 251.05%	4,999 $19,000
Q1 2019 May 14, 2019	SELL	$2.61 - $4.35 $911,537 - $1.52 Million	-349,248 Reduced 99.59%	1,424 $5,000
Q4 2018 Feb 14, 2019	BUY	$2.17 - $6.12 $746,623 - $2.11 Million	344,066 Added 5208.39%	350,672 $838,000
Q3 2018 Nov 14, 2018	SELL	$4.39 - $6.85 $588 - $917	-134 Reduced 1.99%	6,606 $41,000
Q2 2018 Aug 14, 2018	BUY	$4.39 - $5.44 $16,098 - $19,948	3,667 Added 119.33%	6,740 $30,000
Q1 2018 May 15, 2018	BUY	$3.21 - $5.21 $9,864 - $16,010	3,073 New	3,073 $14,000
Q4 2017 Feb 14, 2018	SELL	$2.06 - $3.24 $7,004 - $11,016	-3,400 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.76 - $3.71 $9,384 - $12,614	3,400	3,400 $10,000

Others Institutions Holding ADMA

# of Institutions

400

Shares Held

197M

Call Options Held

2.08M

Put Options Held

1.56M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $2.75B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account